@article {1845, title = {Lutein and zeaxanthin supplementation in preterm infants to prevent retinopathy of prematurity: a randomized controlled study.}, journal = {J Matern Fetal Neonatal Med}, volume = {25}, year = {2012}, month = {2012 May}, pages = {523-7}, abstract = {

OBJECTIVES: Lutein and its isomer zeaxanthin (L/Z) function in the eye as antioxidant agents and blue-light filters. Our aim was to evaluate whether their administration could help decrease the occurrence of retinopathy of prematurity (ROP) in preterm infants.

METHODS: Infants with gestational age <=32 weeks were randomly assigned to receive a daily dose of L/Z (0.14 + 0.006 mg) or placebo until discharge.

RESULTS: ROP occurrence was similar in the L/Z (11/58; 19\%) and placebo (15/56; 27\%) groups, as the occurrence of ROP at each stage and the need of eye surgery.

CONCLUSION: L/Z supplementation was ineffective in preventing ROP in preterm infants and did not affect the outcome at discharge of our patients.

}, keywords = {Antioxidants, Drug Administration Schedule, Drug Combinations, Female, Humans, Infant, Newborn, Infant, Premature, Logistic Models, Lutein, Male, Retinopathy of Prematurity, Risk Factors, Treatment Outcome, Xanthophylls, Zeaxanthins}, issn = {1476-4954}, doi = {10.3109/14767058.2011.629252}, author = {Dani, Carlo and Lori, Ilaria and Favelli, Federica and Frosini, Saverio and Messner, Hubert and Wanker, Petra and De Marini, Sergio and Oretti, Chiara and Boldrini, Antonio and Massimiliano, Ciantelli and Bragetti, Patrizia and Germini, Cristiana} }